CE

Creative Medical Technology Holdings IncNASDAQ CELZ Stock Report

Last reporting period 30 Sep, 2024

Updated 26 Nov, 2024

Last price

Market cap $B

0.004

Micro

Exchange

XNAS - Nasdaq

CELZ Stock Analysis

CE

Uncovered

Creative Medical Technology Holdings Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

15/100

Low score

Market cap $B

0.004

Dividend yield

Shares outstanding

14.076 B

Creative Medical Technologies, Inc. develops novel regenerative medicine and stem cell technologies. The company is headquartered in Phoenix, Arizona. The company went IPO on 2009-05-01. The firm is focused on immunology, urology, neurology, and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The firm conducts its commercial operations through its subsidiary, Creative Medical Technologies, Inc. (CMT). CMT markets and sells its CaverStem and FemCelz disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction (ED) and female sexual dysfunction, respectively. Its products include CaverStem, FemCelz, StemSpine, ImmCelz and OvaStem. StemSpine is a regenerative stem cell procedure for the treatment of degenerative disc disease. ImmCelz is a universal donor stem cell therapy for stroke treatment. OvaStem is a stem cell therapy for premature ovarian failure. The company is also focused on the use of its technologies covering treatments for various diseases.

View Section: Eyestock Rating